Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | GALR3 | O60755 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MPI | P34949 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10084821 | 1.00 | KMT2A (0.58) | KMT2AMEN1GAALRRK2IDO1 | |
| SCHEMBL19586520 | 0.98 | KMT2A (0.57) | KMT2AMEN1GAALRRK2IDO1 | |
| SCHEMBL458707 | 0.86 | LRRK2 (0.51) | KMT2AMEN1LRRK2IDO1ALDH1A1 | |
| SCHEMBL30455414 | 0.86 | LRRK2 (0.51) | KMT2AMEN1LRRK2IDO1ALDH1A1 | |
| SCHEMBL10085220 | 0.86 | LRRK2 (0.51) | KMT2AMEN1LRRK2IDO1ALDH1A1 | |
| SCHEMBL9853498 | 0.85 | LRRK2 (0.50) | KMT2AMEN1LRRK2IDO1ALDH1A1 | |
| SCHEMBL3063202 | 0.83 | KMT2A (0.60) | KMT2AMEN1GAALRRK2IDO1 | |
| SCHEMBL10084818 | 0.82 | KMT2A (0.53) | KMT2AMEN1GAALRRK2IDO1 | |
| SCHEMBL19449866 | 0.81 | LRRK2 (0.57) | KMT2AMEN1GAALRRK2IDO1 | |
| SCHEMBL23754666 | 0.80 | LRRK2 (0.53) | LRRK2IDO1TDO2KDRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3454895-B1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NAJIT TECH INC (US) | 2024-03-27 | — | — | EP | claimed |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2023-12-19 | — | — | US | claimed |
| US-20230346910-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | Najít Technologies, Inc. | 2023-11-02 | — | — | US | claimed |
| US-11633470-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | NAJIT TECHNOLOGIES, INC. (US) | 2023-04-25 | — | — | US | claimed |
| US-20220241395-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | Najít Technologies, Inc. | 2022-08-04 | — | — | US | claimed |
| US-20210196812-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | Najít Technologies, Inc. | 2021-07-01 | — | — | US | claimed |
| US-10744198-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | NAJIT TECHNOLOGIES, INC. (US) | 2020-08-18 | — | — | US | claimed |
| US-20200108094-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-09 | — | — | US | claimed |
| US-20190201520-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-04 | — | — | US | claimed |
| CN-106699766-B | It is a kind of with the spiral shell isatin β-thiosemicarbazone derivative and its synthetic method of antibacterial activity and application | 浙江师范大学 | 2018-08-07 | — | — | CN | claimed |
| WO-2017197034-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | NAJIT TECHNOLOGIES, INC. (US) | 2017-11-16 | — | — | WO | claimed |
| WO-2017197035-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | NAJIT TECHNOLOGIES, INC. (US) | 2017-11-16 | — | — | WO | claimed |
| CN-106699766-A | Spiro-isatin thiourea derivative with antibacterial activity as well as synthesis method and application of derivative | 浙江师范大学 | 2017-05-24 | — | — | CN | claimed |
| EP-1495125-B1 | VAC-BAC SHUTTLE VECTOR SYSTEM | US GOV HEALTH & HUMAN SERV (US) | 2010-06-16 | — | — | EP | claimed |
| US-7494813-B2 | VAC-BAC shuttle vector system | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-02-24 | — | — | US | claimed |
| US-20050124070-A1 | VAC-BAC shuttle vector system | DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, THE | 2005-06-09 | — | — | US | claimed |
| EP-1495125-A2 | VAC-BAC SHUTTLE VECTOR SYSTEM | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003087330-A2 | VAC-BAC SHUTTLE VECTOR SYSTEM | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-10-23 | — | — | WO | claimed |
| WO-2001093866-A1 | COMPOUNDS WITH ANTI-HSV ACTIVITY | UNIHART CORPORATION (IE) | 2001-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241395-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | DUOX2, DUOX1, TET2 | KMT2A 1061/4885MEN1 2602/4885GAA 1798/4885 |
| US-20210196812-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | OGG1, EIF2AK2, AS3MT | KMT2A 1141/4885MEN1 3572/4885GAA 417/4885 |
| US-20230346910-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | DUOX2, DUOX1, TET2 | KMT2A 1061/4885MEN1 2602/4885GAA 1798/4885 |
| US-11633470-B2 | Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process | DUOX2, DUOX1, TET2 | KMT2A 1061/4885MEN1 2602/4885GAA 1798/4885 |
| US-20200108094-A1 | INACTIVATING PATHOGENS AND PRODUCING HIGHLY IMMUNOGENIC INACTIVATED VACCINES USING A DUAL OXIDATION PROCESS | DUOX2, DUOX1, TET2 | KMT2A 1061/4885MEN1 2602/4885GAA 1798/4885 |
| US-20190201520-A1 | INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION | OGG1, EIF2AK2, AS3MT | KMT2A 1230/4885MEN1 3648/4885GAA 403/4885 |
| US-11844832-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | KMT2A 1141/4885MEN1 3572/4885GAA 417/4885 |
| US-10744198-B2 | Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production | OGG1, EIF2AK2, AS3MT | KMT2A 1230/4885MEN1 3648/4885GAA 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.